The Pharmaceutical/ Supplement Debate
Is it not time that we stop relying so heavily on Pharmaceuticals? We are creating our own Hell on Earth with our demands on the Medical systemand by continuing with our own bad habits.There are absolute alternatives that most of us do not understand or embrace.
Pharmaceutical companies will bend over backwards to create a drug for a condition. Even though there are natural alternatives clinically proven, in the SAME research facilities to be more effective, billions of dollars are spent to find a drug alternative that is known to cause significant side-effects. Financial gain is sustaining the momentum on this practice, however we are the ones creating the demand for it by not taking proper care! Our Medical facilities cannot keep up with the demands we place on them either!
Medical professionals are not taught an overwhelming amount of nutrition. They understand how treat a condition with pharmaceuticals, and they are, for the most part, bound to follow that training.
The popularity of dietary supplements has created a great deal of research on the interactions of drugs and supplements.
Due to a large rapidly aging population relying on pharmaceutical products, it is found by some of the research, there is a monumental risk that these individuals will suffer nutritional inadequacies, or worse, nutritional deficiencies induced by the use of pharmaceuticals. The impact of waste from these products flushing through our bodies and down the drain, are another contributing factor to global environmental catastrophes and global epidemic health problems.
Another example was the delayed publishing the news of the radioactive spill of Tritium at the Automic Energy Canada,Chalk River nuclear facility in December. It is well known that this facility is in desperate need of upgrade for public safety, however this plant generates 70% of the global supply of isotopes used for Cancer radiation and medical diagnostics. Some are downplaying it as “just a minor amount”, not to worry.
But , consider that a great deal of cancers would not occur if we had proper nutrition. We also need to reduce our exposures to harmful elements. We all know this, but were are running our routines, no time to change gears. It’s somebody else’s problem, somebody else’s fault. Are we really helpless to effect change?
Calcium de Glucarte is a formulation which has given several Cancer patients years of life and a quality of life. Calcium D-Glucarate’s effect is to favor the body’s natural defense mechanism for eliminating carcinogens thus preventing many forms of cancer, including lung, breast, prostate, and colon. It was proven in several studies done at the MD Anderson Cancer Clinic in Houston , Texas. There are no toxic effects from taking D-Glucararate. I have heard of many people gaining several years of quality life using this. How many people have ever heard of this ? Do you wonder why ?
Would there not be less of a demand for the nuclear facility in Chalk River and those isotopes if we were to personally place more focus on managing our health and environment a bit better?
Statins are globally used to assist the Cardiovascular epidemic reduce cholesterol. This is 40 billion industry in North America. The Statins are known reduce CoQ10 in your body- this is extremely important for heart health. As CoQ10 decreases people develop congestive heart failure.
Our bodies are not chemical processing plants. I doubt that evolution is going to have us caught up to that any time soon either! Why are we, marching so steadfastly to that Pharmaceutical pit here in North America? Heart disease is 80% preventable, and yet it is the leading cause of death globally. .
Diuretics used to decrease the volumes of salt and or water in our bodies to reduce blood pressure. They do this very effectively. The trade-off is depletion of the essential minerals magnesium and potassium, and the Vitamin-B , thiamin responsible for neuro-function and carbohydrate metabolism.
Metabolismis important!! We have an epidemic of Obesity epidemic to the point where we are thinking it might just be a good idea to get those fat kids on Statins… ?We have solid science on natural alternatives that absolutely work.Why is that not part of the medical regiment?
Pharmaceuticals provide important benefits to patients with medical problems but consumers should beware of the potential depletion of nutrients associated with their use.
We have absolute solid science on many natural alternatives that address serious conditions. Pharmaceuticals provide important benefits to patients with medical problems. To learn more on Calcium D-Glucarate go to the link above WELLNESS, WOMEN’s Health – Women’s Formula Plus, MEN’s HEALTH- Men’s Formula Plus. For further information on Bios Life, the only clinically proven natural alternative for Statin Drugs see HEALTH SOLUTIONS, Read about Bios Life, read about the Heart.
I believe that the responsibility is ours to pay attention to our lifestyle alternatives. We are running out of time!
ref: Daniel Fabricant, Ph.D., VP of Scientific and Regulatory Affairs, Natural Products Association
1 Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001;24:258-272.; Wortmann RL. Lipid Lowering Agents and Myopathy. Curr Opin Rheumatol 2002;14:643-647.; Seehusen DA, Asplund CA, Johnson DR, Horde K, South Med J. 2006;99(3):250-254.
2 Chiang C, Pella D, Singh R. Coenyzme Q10 and adverse effects of statins. J Nutritional and Environmental Medicine 2004;14:17-28;Rundek T, Naini A, Sacco R, et al.Atorvastatin decreas- es the coenzyme Q 10 level in the blood of patients at risk for cardiovascular disease stroke.Arch Neurol 2004;61:889-892.
3 Langsjoen PH, Langsjoen AM.The clinical use of HMG CoA-reductase inhibitors and the associ- ated depletion of CoQ10: a review of animal and human publications. BioFactors 2003;18:101- 111.;Murray M.Encyclopedia of Nutritional Supplements.Rocklin, CA:Prima Health, 1996.
4 Coenzyme Q10 monograph.Vol.2005:Natural Medicines Comprehensive Database, 2005.
5 Al-Ghamdi SM, Cameron EC, and Sutton RA. Am J Kidney Dis. 1994, 24(5):737-52; Brucato A, Bonati M, Gaspari F, et al.J Toxicol Clin Toxicol.1993, 31(2):341-4;Cohen N, Golik A, Dishi V, et al.Miner Electrolyte Metab.1996, 22(4):248-52;Iseri LT, Freed J, and Bures AR.Am J Med.1975, 58(6):837-46; Lucker PW and Witzmann HK. Magnesium. 1984, 3(4-6):265-73; Quamme GA Kidney Int. 1997, 52(5):1180-95; Rolla G, Bucca C, Bugiani M, et al. Magnes Trace Elem. 1990, 9(3):132-6.;Ryan MP.Magnesium.1986, 5(5-6):282-92.;Schwinger RH and Erdmann E.Methods Find Exp Clin Pharmacol.1992, 14(4):315-25.26) Cohen L, Kitzes R, and Shnaider H.Magnesium. 1985, 4(4):176-81.;Dyckner T and Wester PO.Am J Med.1987, 82(3A):11-7.;Hollifield JW.Am J Med.1984, 77(5A):28-32.;Malini PL, Strocchi E, Valtancoli G, et al.Magnes Res.1990, 3(3):193- 6.; Nicholls MG. Am J Cardiol. 1990, 65(10):17E-21E; discussion 22E-23E; Petri M, Cumber P, Grimes L, et al. Age Ageing. 1986, 15(3):151-5.; Gettes LS, Circulation. 1992, 85(1Suppl):170- 176.;Hollifield JW.Am J Med.1984, 77(5A):28-32.;Robertson JI.Eur Heart J.1984, 5(suppl A):25- 28.; Physicians Desk Reference, 51st ed, Montavale, NJ:Medical Economics Co, 1997, 1268.; Rastogi S, BaylissJM, Nascimento L, et al.Kidney Int.1985, 28(5):801-807;Valmin K, Hansen T, and Ronsted P, Pharmatherapeutica.1980, 2(5):296-304.
6 Seligmann H., et al.The American Journal of Medicine, 1991. 91:151-155; Shimon I, et al.The American Journal of Medicine. 1995. 98:485-490; Yui Y., Itokawa Y., Kawai C. Cardiovascular Research.1980.14:537-540;Zangen A., Botzer D., Zangen R., Shainberg A.European Journal of Pharmacology.1998.361:151-155.
7 MacLaughlin EJ, Sleeper RB, McNatty D, and Raehl CL, Ther Clin Risk Manag. 2006; 2(3): 281–295.
8 Thorp VJ, J Am Diet Assoc.1980;76(6):581-4;Webb JL, J Reprod Med.1980;25(4):150-6.
CBC Canada Updated: Tue Jan. 27 2009 17:48:48
Stewart A. Lonky, MD, FACP
- Walaszek, Z., Hanausek, M., Szemraj, J., and Adams, A.K. 1998,
D-Glucarate acid as a prospective tumor marker. Meth. Mol. Med., 14,
- Walaszek, Z., Szemraj, J., Adams, A.K., and Hanausek, M. 1992,
Reduced levels of D-Glucaric acid in mammary tumor-bearing hosts and
the effect of its supplementation during estrogen replacement and tamoxifin
therapy. Proc. Am. Assoc. Cancer Res. 37: 183.
- Heerdt, A.S., Young, C.W.., and Borgen, P.I., 1995, Calcium Glucarate
as a chemopreventative agent in breast cancer., Isr. J. Med. Sci. 31:
- Walaszek, Z. Chemopreventative properties of D-Glucaric acid
derivatives. Cancer Bull 1993; 45: 453-457.
- Walaszek, Z., Szemraj, J., Adams, A.K., Kordari, P., and Hanausek, M.
1992, Reduced levels of D-Glucaric acid in mammary tumor-bearing Host.
Breast Cancer Res. Treat., 375: 108.
- Walaszek, Z., Hanausek, M., Adams, A.K. and Sherman, U. 1991,
Cholesterol lowering effects of dietary D-Glucarate. Faseb J., 5: A930.
- Walaszek, Z., Hanausek, M., Sherman, U. and Adams, A.K. 1990,
Antiproliferative effect of dietary glucarate on the Sprague Dawley in rat
mammary gland. Cancer Lett. 49: 51-57.
- Walaszek, Z., Adams, A.K., Sherman, U., Viaje, A., Rotstein, J.B.,
Hanausek, M. and Slaga, T.J. 1990, Antiproliferate effects of Calcium
D-Glucarate (CG) and D-glucaro-1,4-lactone (GL) on the rat mammary
gland, colon and mouse skin. Proc. Am. Assoc. Cancer Res., 31: 124. p>
- Walaszek, Z. 1990, Potential use of D-Glucarate acid derivatives in
cancer prevention. Cancer Lett. 54: 1-8.
- DiGiovanni, J., 1990, Inhibition of chemical carcinogenesis. In:
Chemical Carcinogenesis and Mutagenesis II, Cooper, C.S. and Grover,
P.L. (eds.), Springer Verlag, Berlin, pp. 159-224.
- Walaszek, Z., Adams, A.K., and Flores, F., 1989, Inhibition of
7,12-dimethylbenz(a)-anthracene(DMBA)-induced rat mammary
carcinogenesis by glucarate. Proc. Am. Assoc. Cancer Res., 30: 170.
- Abbou-Issa, H., Koolemans-Beynen, A., Minton, J.P. and Webb, T.E.,
1989, Synergistic interaction between 13-cis-retinoic acid and glucarate:
activity against rat mammary tumor induction and MCF-7 cells. Biochem.
Biophys. Res. Commun.,163: 1364-1369.
- Dwivedi, C., Oredipe, O.A., Barth, R.F., Downie, A.A. and Webb, T.E.,
1989, Effects of the experimental chemopreventative agent, glucarate on
intestinal carcinogenesis in rats. Carcinogenesis, 10: 1539-1541.
- Oredipe, O.A., Barth, R.F., Dwivedi, C. and Webb, T.E., 1989,
Chemopreventative activity of dietary glucarate on azoxymethane-induced
altered hepatic loci in rats. Res. Commun. Chem. Pathol. Pharmacol., 65:
- Dwivedi. C., Downie, A.A. and Webb, T.E., 1989, Modulation of
chemically initiated and promoted skin tumorigenesis in CD-1 mice by
dietary glucarate. J. Environ. Path. Toxicol. Oncol., 9: 253-259.
- Walaszek, Z., Hanausek, M., Sherman, U., Del Rio, M. and Adams,
A.K., 1989, Effects of (+) glucaric acid derivatives and tamoxifen on human
breast cancer cells (MCF-7). Breast Cancer Res. Treat., 14: 175.
- Walaszek, Z., Flores, F. and Adams, A.K., 1988, Effect of dietary
glucarate on estrogen receptors and growth of 7,12-dimethylbenz[a]
anthracene-induced rat mammary carcinomas. Breast Cancer Res. Treat.,
- Walaszek, Z., Hanausek-Walaszek, M. and Webb, T.E., 1988,
Repression by sustained release or glucuronidase inhibitors of chemical
carcinogen-mediated induction of a marker oncofetal protein in rodents. J.
Toxicol. Environ. Health, 23: 15-27.
- Abbou-Issa, H.M., Duruibe, V.A., Minton, J.P., Larroya, S., Dwivedi,
C., and Webb, T.E., 1988, Putative metabolites derived from dietary
combinations of calcium glucarate and N-(4hydroxypheny)retinamide act
synergistically to inhibit the induction of rat mammary rumors by
7,12-dimethylbenz[a]-anthracene. Proc. Natl. Acad. Sci. USA. 85:
- Oredipe, O.A., Barth, R.F., Hanausek-Walaszek, M., Sautins, I.,
Walaszek, Z. and Webb, T.E. 1987, Effects of an inhibitor of
B-glucuronidase on hepatocarcinogenesis. Proc. Am. Assoc. Cancer Res.,
- Oredipe, O.A., Barth, R.F., Hanausek-Walaszek, M., Sautins, I.
Walaszek, Z. and Webb, T.E. 1987, Effects of calcium glucarate on the
promotion of diethylnitrosamine-initiated altered hepatic loci in rats.
Cancer. Lett., 38, 95-99.
- Walaszek, Z., Hanausek-Walaszek, M., Minton, J.P. and Webb, T.E.
1986, Dietary glucarate as antipromoter of
7,12-dimethylbenz[a]-anthra-cene-induced mammary tumorigenesis.
- Minton, J.P., Walaszek, Z., Hanausek-Walaszek, M., and Webb, T.E.
1986, B-Glucuronidase levels in patients with fibrocystic breast disease.
Breast Cancer Res. Treat., 8: 217-222.
- Walaszek, Z., Hanausek-Walaszek, M., Webb, T.E., 1986, Dietary
glucarate-mediated reduction of sensitivity of murine strains to chemical to
chemical carcinogenesis. Cancer Lett., 33: 25-32.
This website and its content is not intended to be a substitute tor professional medical advice, consultation, treatment or diagnosis. Always seek the advice of a qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen in any of the content. Reliance on any information is solely at your own risk.
The notes herein are notes taken on how certain health challenges and conditions were managed nutritionally in the past. They in no way are meant to prescribe or diagnose for individuals. People with serious health concerns should always consult with a medical practitioner and follow ‘best health rules and make decisions on their health personally and or with the guidance of a practitioner they trust.